Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 1 day ago
- 2 min read
06/05/2026
InflaRx announced advancement of Izicopan in AAV and select renal diseases (Ref)
InflaRx announced that it intended to develop izicopan (an oral C5a receptor inhibitor) in ANCA-Associated Vasculitis (AAV).
InflaRx was conducting Phase 2 planning for izicopan in AAV and was evaluating the feasibility of multiple development approaches, including the potential for an expedited path to the commercial market, with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseases.
The Company estimated it would have sufficient funds for currently planned clinical development activities and ongoing operations through 2029.
InflaRx stated it would continue to engage in dialog with potential collaborators to advance its development goals with izicopan across all geographies.
SynAct Pharma completed dosing for the last patient in Phase 2b study for RA (Ref)
SynAct Pharma AB announced that it had successfully completed dosing of the last patient in the Phase 2b ADVANCE study of resomelagon in newly diagnosed patients with Rheumatoid Arthritis (RA).
The company expected topline results from Phase 2b study to be shared in June 2026.
Thomas Jonassen, Chief Scientific Officer of SynAct Pharma said - “We are happy to complete the dosing of the last patient. With the study we aim to demonstrate the concept of improving early resolution of disease symptoms and thereby stopping or delaying disease progression without the risks associated with immunosuppressant therapies. With positive data we will commence Phase 3 readiness activities, and we will move strategic discussions forward to form the strongest possible path to getting resomelagon to patients suffering from RA worldwide.”
